LYDIA GIRON: Open Payments
NPI 1912558305 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$904 in 32 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $944 · 2025 $904
Food & beverage: $904
| Company | Payments | Amount |
|---|---|---|
| SI-BONE, INC. | 4 | $249 |
| ABBVIE INC. | 11 | $163 |
| Lilly USA, LLC | 2 | $144 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $97 |
| Novo Nordisk Inc | 3 | $80 |
| Teva Pharmaceuticals USA, Inc. | 2 | $59 |
| Noven Therapeutics, LLC | 2 | $47 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| Smith+Nephew, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
Products named: VRAYLAR, MOUNJARO, CAPLYTA, Wegovy, UZEDY, Xelstrym, SPRAVATO, COLLAGENASE SANTYL.
Industry payments across TX — which companies pay providers there.
